17 completed, 5 terminated, 1 active not recruiting, 1 withdrawn. 12 Phase 1, 9 Phase 2, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Terminated 3, Active not recruiting 1 |
| Phase 2 | 9 | Completed 6, Terminated 2, Active not recruiting 1 |
| Not applicable | 4 | Completed 3, Withdrawn 1 |
Follow Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative: new trials by email Literature Review of Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative trials Research Report on Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia | Phase 2 | Completed | OHSU Knight Cancer Institute | 51 | 2014-07-08 | 2020-11-16 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia cefepime hydrochloride - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 70 | 2011-02-01 | 2018-07-18 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Not applicable | Completed | Roswell Park Cancer Institute | 62 | 2009-01-14 | 2019-11-13 |
| Aflibercept in Treating Patients With Myelodysplastic Syndromes ziv-aflibercept, laboratory biomarker analysis, pharmacological study - Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2007-09-01 | 2015-01-08 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia fludarabine phosphate, triapine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-01-06 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Belinostat, Azacitidine, Laboratory Biomarker Analysis - Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 56 | 2006-06-01 | 2014-12-23 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders vorinostat, cytarabine, etoposide - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2006-05-01 | 2013-05-03 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis - Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 77 | 2006-01-01 | 2020-01-31 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 12 | 2005-03-01 | 2017-05-30 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation - Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome | Phase 2 | Completed | Fred Hutchinson Cancer Center | 210 | 2004-11-01 | 2019-10-30 |
| Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Cytology Specimen Collection Procedure - Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Completed | Children's Oncology Group | 2545 | 2003-10-13 | 2018-07-19 | |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer ipilimumab, therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2003-04-01 | 2013-03-27 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (24) · Leukemia, Myelomonocytic, Chronic (18) · Leukemia, Myeloid, Acute (17) · Myeloproliferative Disorders (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Primary Myelofibrosis (14) · Leukemia, Myeloid, Accelerated Phase (12) · Blast Crisis (11) · Burkitt Lymphoma (11) · Leukemia, Neutrophilic, Chronic (11) · Lymphoma, Large B-Cell, Diffuse (11) · Hodgkin Disease (10) · Leukemia, Myeloid, Chronic-Phase (10) · Lymphoma, Follicular (10)
Bone Marrow Diseases (24) · Chronic Disease (24) · Disease Attributes (24) · Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Leukemia (24) · Leukemia, Myeloid (24) · Neoplasms by Histologic Type (24) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Neoplasms (23) · Myelodysplastic-Myeloproliferative Diseases (22) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Leukemia, Lymphoid (16)
fludarabine phosphate (5) · Whole-Body Irradiation (4) · CTLA-4 Antigen (3) · Ipilimumab (3) · Mycophenolic Acid (3) · Peripheral Blood Stem Cell Transplantation (3) · Sunitinib (3) · Azacitidine (2) · Cyclosporine (2) · Imatinib Mesylate (2) · Sirolimus (2) · Therapeutics (2) · Vorinostat (2) · ruxolitinib (2) · venetoclax (2)
National Cancer Institute (NCI) (12) · Fred Hutchinson Cancer Center (3) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · Wake Forest University Health Sciences (2) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · Martin, Paul (1)
United States (22) · Canada (4) · New Zealand (2) · Australia (1) · Denmark (1) · Germany (1) · Italy (1) · Puerto Rico (1) · Switzerland (1)
Brenda Sandmaier (3) · Douglas Ross (1) · Ewa Carrier (1) · Frank Hodi (1) · George Chen (1) · Janet Tooze, PhD (1) · John Deeken (1) · John Williamson (1) · Judith Karp (1) · Kim-Hien Dao (1) · Lara Davis, MD (1) · Mark Kirschbaum (1) · Mark Minden (1) · Maryam Fouladi (1) · Nicholas Short (1)
PMID 32499241, PMID 18974373, PMID 22259028, PMID 24362550, PMID 24474568, PMID 25085357, PMID 25180155, PMID 30630975, PMID 31880950, PMID 37422688, PMID 39863139
P01CA018029 (3), P30CA015704 (3), U01CA062491 (2), N01CM62202 (1), N01CM62203 (1), N01CM62209 (1), P30CA006973 (1), P30CA014599 (1), P30CA124435 (1), R01CA093891 (1), R21CA105776 (1), U01CA062487 (1), U01CA062502 (1), U01CA062505 (1), U01CA069852 (1)